Leaflet VALGANCICLOVIR TEVA 450mg film-coated tablets
Indicated for: cytomegalovirus infection
Route of administration: oral
Substance: valganciclovir (antiviral)
ATC: J05AB14 (Antiinfectives for systemic use | Direct acting antivirals | Nucleosides and nucleotides excl. reverse transcriptase inhibitors)
Dose adjustment may be needed in kidney disease.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Valganciclovir is an antiviral medication used for the treatment and prevention of cytomegalovirus (CMV) infections in immunocompromised patients, such as those who have undergone organ transplantation or are infected with HIV. It is a prodrug of ganciclovir, which is active against CMV by inhibiting viral DNA synthesis, thereby preventing viral replication.
The medication is administered orally, usually once or twice daily, depending on the therapeutic indication and the patient's condition. The dosage is adjusted based on the patient's renal function to reduce the risk of toxicity.
Common side effects include nausea, diarrhea, anemia, neutropenia, and fatigue. In rare cases, severe adverse reactions such as renal failure, severe myelosuppression, or allergic reactions may occur.
Valganciclovir is an essential medication for managing CMV infections in immunocompromised patients, helping to prevent severe complications associated with this viral infection.
General data about VALGANCICLOVIR TEVA 450mg
- Substance: valganciclovir
- Date of latest medicines list: 01-07-2020
- Product code: W60756001
- Concentration: 450mg
- Pharmaceutical form: film-coated tablets
- Quantity: 60
- Product type: Generic medicine
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for valganciclovir
Concentrations available for valganciclovir
- 450mg
- 50mg/ml